2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-150630
    ALR2-IN-1 2799695-54-6 99.33%
    ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC50=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research.
    ALR2-IN-1
  • HY-151193
    NNMT-IN-3 3031493-74-7 98%
    NNMT-IN-3 (Compound 14) is a potent and selective nicotinamide N-methyltransferase (NNMT) inhibitor, with IC50 values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. NNMT-IN-3 can be used in the research of diseases such as obesity, type 2 diabetes and cancer.
    NNMT-IN-3
  • HY-15133A
    PTP1B-IN-3 diammonium 2702673-78-5
    PTP1B-IN-3 diammonium is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 diammonium has antidiabetic and anticancer effects.
    PTP1B-IN-3 diammonium
  • HY-151369
    AV123 233605-81-7 99.60%
    AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC50=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC50=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases.
    AV123
  • HY-151931
    JA-ACC 371778-55-1 98%
    JA-ACC (Jasmonyl-ACC) is a derivative of 1-aminocyclopropane-1-carboxylic acid (ACC). ACC is the direct precursor of the plant hormone ethylene. JA-ACC inhibits root growth in Arabidopsis and the inhibition is independent of jasmonic acid (JA) signaling.
    JA-ACC
  • HY-151959
    FXR agonist 4 3025841-47-5 99.37%
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD).
    FXR agonist 4
  • HY-152217
    Clathrin-IN-2 2650733-69-8 98.77%
    Clathrin-IN-2 is potent inhibitor of clathrin mediated endocytosis (CME) with an IC50 value of 2.3 μM. Clathrin-IN-2 also has inhibitiory for dyn I GTPase with an IC50 value of 7.7 μM.
    Clathrin-IN-2
  • HY-153132
    mGluR3 modulator-1 374548-18-2 98.67%
    mGluR3 modulator-1 (compound 3) is a mGluR3 modulator, with an EC50 of 1-10 μM in HEK293T-mGluR-Gqi5 Calcium Mobilization Assay.
    mGluR3 modulator-1
  • HY-153463
    Diosuxentan 2305865-93-2 98%
    Diosuxentan is an inhibitor of ETA. Diosuxentan can be used in research for cardiovascular, renal and neuronal inflammation diseases.
    Diosuxentan
  • HY-153675
    BCPA 547731-67-9 98.51%
    BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research.
    BCPA
  • HY-153893
    Magmas-IN-1 1251957-89-7 98%
    Magmas-IN-1 (compound 9) is a small molecule Magmas inhibitor (SMMI). Magmas is mitochondria associated，granulocyte-macrophage colony stimulating factor signaling molecule，as well as a GM-CSF inducible gene in myeloid cells. Magmas-IN-1 inhibits Magmas and modulates mitochondrial function. Magmas-IN-1 also inhibits proliferation in yeast at 4 μM.
    Magmas-IN-1
  • HY-153968
    URAT1&XO inhibitor 1 2669726-78-5 99.96%
    URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research.
    URAT1&XO inhibitor 1
  • HY-153972
    URAT1&XO inhibitor 2 1239488-96-0 98.69%
    URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia.
    URAT1&XO inhibitor 2
  • HY-154928
    GW6340 405910-78-3 99.64%
    GW6340 is an intestinal-specific LXR agonist. GW6340 promotes macrophage reverse cholesterol transport (mRCT).
    GW6340
  • HY-155525
    Anti-NASH agent 1 2409685-41-0 98.49%
    Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect.
    Anti-NASH agent 1
  • HY-156023
    SIRT1 activator 2 863589-52-0 99.28%
    SIRT1 activator 2 is a SIRT1 activator with an ED50 value <5 μM. SIRT1 activator 2 modulates SIRT1 deacetylase activity. SIRT1 activator 2 can be used for aging research.
    SIRT1 activator 2
  • HY-156049
    MG-H1 149204-50-2
    MG-H1 is a receptor of advanced glycation end products (RAGE) ligand with a Kd of 4.12 nM. MG-H1 can bind to human umbilical vein endothelial cell. MG-H1 can be used for research of diabetes.
    MG-H1
  • HY-156276
    SP4e 3086376-12-4 99.72%
    SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice.
    SP4e
  • HY-156518
    Glucose-malemide 2093979-63-4 99.72%
    Glucose-malemide is a glycoconjugate consisting of a glucose molecule and a maleimide group of a linker molecule. Glucose-malemide can be used in the preparation of glucose-responsive insulin delivery compositions, thereby conjugating glucose to insulin.
    Glucose-malemide
  • HY-15656S
    Ceritinib-d7 1632484-77-5 ≥98.0%
    Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
    Ceritinib-d7
Cat. No. Product Name / Synonyms Application Reactivity